It’s time to switch gears and talk about neoantigens again… we’ve been covering this niche since 2015, as you can see from the relevant magazine page.

Aside from today’s expert interview, there will be an important update coming at ESMO in the Fall so this is a good time to set the scene ahead of time.

In our latest discussion, we cover some of the AI/deep learning aspects of the technological developments with a view to how they connect with the clinical challenges and progress since they don’t obviously exist in isolation.

As always there are important lessons and learnings along the way, such is the roller coaster of R&D, especially in oncology…

BSB subscribers can learn more about our latest interview on how deep learning can be applied to the neoantigen niche – you can read all about it by logging in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

Posted by